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In sub-Saharan Africa, limited epidemiological data describe cancer burden among ART users. Integrated 
cancer screening and management in HIV clinics, especially for KS and cervical cancer, remain important 
priorities in the current Malawi context.  
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ABSTRACT 
Background 
With antiretroviral therapy (ART), AIDS-defining cancer incidence has declined and non-AIDS defining 
cancers are now more frequent among HIV-infected populations in high-income countries. In sub-
Saharan Africa, limited epidemiological data describe cancer burden among ART users.  
Methods 
We used probabilistic algorithms to link cases from the population-based cancer registry with electronic 
medical records supporting ART delivery in the Malawi’s two largest HIV cohorts, Lighthouse Trust (LT; 
2007-2010) and Queen Elizabeth Central Hospital (QECH; 2000-2010). Age-adjusted cancer incidence 
rates (IR) and 95% confidence intervals were estimated by cancer site, early versus late incidence 
periods (4 -24 and  >24 months after ART start), and WHO stage among naïve ART initiators enrolled for 
at least 90 days.  
Results 
We identified 4,346 cancers among 28,576 persons. Most people initiated ART at advanced WHO stage 
(LT stage 3/4: 55%; QECH stage 3/4: 66%); 12% of patients had prevalent malignancies at ART initiation, 
which were predominantly AIDS-defining eligibility criteria for initiating ART. Kaposi sarcoma (KS) had 
the highest IR (634.7 per 100,000 person-years), followed by cervical cancer (36.6). KS incidence was 
highest during the early period 4-24 months after ART initiation. Non-AIDS defining cancers (NADC) 
accounted for 6% of new cancers.  
Conclusions 
Under historical ART guidelines, NADC were observed at low rates, and were eclipsed by high KS and 
cervical cancer burden. Cancer burden among Malawian ART users does not yet mirror high-income 
countries. Integrated cancer screening and management in HIV clinics, especially for KS and cervical 
cancer, remain important priorities in the current Malawi context.  
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SUMMARY  
Kaposi sarcoma and cervical cancer dominate the cancer burden among antiretroviral therapy users in 
Malawi under historical treatment guidelines. A broad spectrum of non-AIDS defining malignancies may 
be an emerging concern among aging HIV populations in Africa.  
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INTRODUCTION  
Three AIDS-defining malignancies, Kaposi sarcoma (KS), cervical cancer, and non-Hodgkin lymphoma 
(NHL) are among the top 10 cancers in sub-Saharan Africa (SSA), where 70% of global HIV burden is 
concentrated [1, 2]. Rapid scale-up of antiretroviral therapy (ART) availability over the past decade [1] is 
likely to affect regional cancer burden. In high-income countries, cancer risk among HIV populations is 
evolving, with notable declines in risk of KS, NHL, and some non-AIDS defining cancers (NADC) over the 
course of ART expansion since 1996 [3]. The burden of certain NADC is now projected to increase and 
surpass that of AIDS-defining cancers (ADC) due to growth and aging of the population living with HIV 
[4]. But extrapolations from high-income countries may not apply to SSA, where delays in accessing HIV 
care are substantial, advanced immunosuppression at ART initiation is common [5], and prevalence of 
oncogenic viral infections is high [6]. Epidemiological evidence is therefore needed to understand cancer 
trends specifically in SSA.  
In the Malawi HIV-Cancer Match Study, we aim to characterize cancer incidence among ART initiators. In 
Malawi, HIV prevalence is 9% and ART coverage has reached 67%, using a threshold for ART eligibility of 
500 CD4 cells/µL or WHO clinical stages 3 and 4 [7]. Our work differs from previous studies in the region 
[8-10], in that we used two of the largest, actively traced cohorts of ART users in the country over a 
period spanning national ART scale-up from 2000 through 2010. We also conducted cross-sectional 
linkage of cancers using the population-based national cancer registry.  
METHODS 
Populations 
Study subjects were HIV-infected people receiving ART at Lighthouse Trust (LT) and the Queen Elizabeth 
Central Hospital (QECH) HIV clinics. In the central region, LT in the capital, Lilongwe, is Malawi’s largest 
public ART provider. In the south, the QECH HIV clinic is situated in Blantyre, Malawi’s second largest 
city. Clinics use electronic monitoring systems to routinely collect demographic information, WHO stage 
at clinic enrollment, ADC clinical diagnoses (KS and cervical cancer only), drug regimens, and patient 
outcomes [11, 12]. Active tracing is used for patient follow-up and ascertainment of vital status. In 
Malawi, CD4 count measurement was historically restricted to stage 1 and 2 patients who were not 
clinically eligible for ART (e.g. stages 3 and 4). For QECH prior to 2011, CD4 counts were not captured in 
the electronic monitoring system and therefore were not available for analysis. Routine HIV RNA 
monitoring in Malawi did not begin until 2011. Therefore, limited CD4 count data and no HIV RNA data 
were available during the time period of our study reflecting practice within the Malawi national HIV 
program. 
The population-based Malawi Cancer Registry (henceforth, the registry) is a founding member of the 
African Cancer Registry Network and one of only five cancer registries from SSA included in WHO 
international estimates of cancer [2]. Active case-finding procedures have been described previously 
[13]. During the study period, QECH in Blantyre housed the sole pathology laboratory for the entire 
country; a second laboratory open at Kamuzu Central Hospital, Lilongwe in 2011 [14].  Thus, historically 
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only 18% of cases were pathologically confirmed, with most cancer diagnoses supported by clinical, 
radiological, and/or laboratory data [13].  Pathology confirmation rate is comparable to that of other 
cancer registries from SSA [15, 16]. 
Electronic medical record linkage 
In the absence of unique personal identifiers, we used probabilistic algorithms to link electronic medical 
records (EMR) from ART cohorts with cancer records. All HIV-infected people initiating ART at QECH 
from 2000 to 2010 or LT from 2007 to 2010 were eligible based on years of registry coverage in Blantyre 
and Lilongwe, respectively. EMR were matched on first and last name, year of birth, sex, and district of 
residence as these identifiers were shared across datasets. Consistent with other SSA settings, date of 
birth was estimated for a substantial proportion of records. Therefore, we allowed for 5-year age 
discrepancies between record pairs during subsequent iterations of the linkage [10]. Highest-weight 
classification was used to classify record pairs as matches, potential matches or non-matches, followed 
by manual adjudication of potential matches (Supplemental Materials p.3 ) [10]. Potential matches were 
manually reviewed and validated through clinical review by three senior Malawian investigators using 
additional oncology treatment data collected by the registry and National Oncology Review Board, when 
available. Data preprocessing and probabilistic record linkage were performed in KNIME Analytics 
Platform Version 2.12.1 (Konstanz, Germany). Data pre- and post-processing were conducted in Stata 14 
(Stata Corporation, College Station, Texas). Analyses were conducted in SAS software 9.4 for Windows 
(Cary, NC, USA). The study was approved by the University of North Carolina Institutional Review Board 
and University of Malawi College of Medicine Research Ethics Committee. 
Study design and statistical analysis 
We used an observational multi-cohort design. ART-naïve individuals were eligible for analysis if they 
had a first clinic date occurring between January 1, 2000 and August 30, 2010 at QECH and January 1, 
2007 and August 30, 2010 at LT, and were followed for at least 90 days. The event of interest was the 
first incident primary cancer diagnosed either clinically or pathologically occurring greater than 90 days 
after ART start. As in other record linkage studies in the United States [17] and Africa [10], the 90 day 
window accounts for clinical workup of prevalent cancers as patients enter the medical system. Cancers 
were identified either through registry linkage or   EMR.We further classified new cancer as early 
incident (4 to 24 months after ART start) and late incident (>24 months). Person-years (py) at risk for 
incident cancer was calculated from 90 days after ART enrollment to the earliest of cancer diagnosis or 
censor due to ART cessation, clinic transfer, last contact, death, or October 1, 2015 administrative 
censor. For those lost to follow-up, person-time at risk included a 180-day window past the missed 
appointment date. Cancer diagnoses that were linked beyond the last date of contact or 180-day 
window were excluded from primary analyses (n=36). Subsequent multiple primaries of different 
anatomical site or histology (n=32) and prevalent malignancies defined as a diagnosis prior to 
enrollment or within 90 days of ART start (n= 3,463) were excluded from incidence rate analysis 
(Supplemental Figures 1-2). Cancer data were coded using the International Classification of Disease for 
Oncology (Supplemental Table 1) [18]. 
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Incidence rates (IR) and 95% confidence intervals (CI) were calculated for individual cancer sites, early 
versus late incidence periods, and WHO stage at clinic enrollment. Rates were age-adjusted to the 2007 
Malawi standard population (ages 0-14, 15-24, 25-34, 35-44, 45-54, 55+ years) [19]. We further 
conducted a sensitivity analysis using only cancer matches with the highest linkage weights to estimate a 
conservative lower bound on cancer-specific IR (Supplemental Table 3). Age-adjusted rates to the World 
Standard are also provided (Supplemental Table 4). 
RESULTS 
Our study included 28,576 new ART users who initiated care at LT (n=15,920) and QECH (n=12,656). 
Median age at enrollment was 33 years (Table 1). New patients tended to initiate ART at an advanced 
WHO stage (LT stage 3: 41%, stage 4: 14%; QECH stage 3: 50%, stage 4: 16%).  
Overall, 4,346 cancers were identified: 16% were identified through record linkage (LT n=202; QECH 
n=477), 84% through the EMR (LT n=3351; QECH n=528). The majority of diagnoses did not overlap 
across data sources (<4%; Supplemental Figures 1-2); information on NHL and NADC was derived 
exclusively from the match with the registry. Pathological confirmation of cancer diagnosis was low and 
varied by clinic site: 3% at LT and 19% at QECH, reflecting diagnostic pathology availability in Lilongwe 
and Blantyre, respectively, during the study period. Prevalence of cancer at time of enrollment was 12%, 
with prevalent cancers being predominantly ADC.  
A total of 23,655 cancer-free individuals at cohort entry were followed for 100,815 py at risk (Table 1). 
Median time on ART was 3.6 years (interquartile range: 0.4, 6.0 years). Most incident cancers occurred 
within 4 to 24 months after starting ART (early incident: n=618; late incident n=265); 21% of early 
incident and 26.4% of late incident diagnoses were identified through linkage to the registry Overall age-
adjusted cancer incidence rate for all sites combined was 689.2 (95%CI 610.2, 768.0; Figure 1). Incidence 
was greatest during the early period of 4-24 months following ART initiation (Table 2).  
AIDS-defining cancers 
KS, cervical cancer and NHL accounted for 94% of new malignancies among new ART users 
(Supplemental Table 1). The majority of KS and cervical cancer cases were diagnosed clinically; 10% and 
27% received a pathological confirmation of diagnosis at LT and QECH, respectively. Squamous cell 
carcinoma was the most common type of cervical cancer (42%), followed by non-specified histological 
types based on clinical diagnosis. All NHL cases were pathologically confirmed.  
Overall KS incidence was 634.6 per 100,000 py on ART (95%CI 558.3, 711.0; Figure 1).  KS occurred most 
frequently in the early incidence period of 4-24 months after starting ART for both men and women 
(Table 2). Early incident KS was greater among men (IR: 525.0; 95%CI 417.5, 615.9) than among women 
(IR: 399.1; 95%CI 324.5, 473.7; Table 2). Men and women experienced 40% increased incidence of KS at 
advanced WHO stage relative to early stage (Table 3); however, this association was not observed 
among clinical stage 4 cases.  
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Cervical cancer was the second most commonly occurring cancer, with an incidence rate of 36.6 (95%CI 
21.4, 51.7; Figure 1). No discernable pattern was observed in early versus late incidence of cervical 
cancer (Table 2). Women with advanced WHO stage had a 70% higher rate of cervical cancer than 
women with early stage HIV, but this association was not significant (Table 3).  NHL was detected at a 
low rate in our study (IR 11.7, 95% CI: 0, 27.0).  
Non-AIDS-defining cancers 
NADC accounted for 6% of the total cancer burden among 2000-2010 ART users (Supplemental Table 1). 
The highest IR were for cancers of the breast (7.1; 95%CI 0, 17.8),  esophagus (6.0, 95%CI: 0.2, 11.8), 
female reproductive cancers (3.7; 95%CI: 0.6, 6.9) , eye and conjunctiva (1.6; 95%CI: 0.2, 3.1), and 
bladder (1.5; 95%CI: 0, 2.9) (Figure 1; Supplemental Table 2). 
Pathological confirmation varied across NADC sites: esophagus (19%), cervix (27%), breast (53%), anus 
(75%), lymphomas (100%), oral cavity/pharynx (100%), eye/conjunctiva (100%). Squamous cell 
carcinoma was the most common type of lip/oral cavity (40%), anus (75%), and eye/conjunctiva (85%) 
malignancy. Squamous cell carcinoma of the esophagus was also predominant (89%). Among breast 
cancers, 71% were infiltrating ductal carcinoma. Infection-associated cancers linked to H. pylori 
(stomach), hepatitis B and C virus (liver), schistosomiasis (bladder), and Epstein-Barr virus (Hodgkin 
lymphoma subtypes) were rarely detected in our study (Figure 1, Supplemental Table 2). 
DISCUSSION  
Our goal in the Malawi HIV-Cancer Match Study was to characterize the burden and spectrum of cancer 
among ART users in Malawi, where HIV prevalence is 9% and one in twenty Malawian adults is now on 
ART [7]. In our study of nearly 29,000 ART users, the overall cancer burden was high and predominantly 
driven by ADC, even during the early era of improving access to ART.  KS was the most common cancer, 
and ADC were a reason for presenting to care for one in eight patients. The incidence of new KS was 
most pronounced during the first two years of ART, but remained high over long-term follow-up. Our KS 
incidence estimates in Malawi are among the highest for ART users in SSA, with other reported rates 
including 77 per 100,000 py in Zimbabwe, 169 in Zambia [20], 270 in Kenya, 340 in Uganda [21], and 432 
in South Africa [9]. High incidence of KS at HIV centers of excellence in Malawi in 2000-2010 are similar 
in magnitude to ART users with CD4 count of 51-100 (IR: 716) in East African ART populations [21]. High 
KS burden in Malawi is likely attributable to the 35% to 88% prevalence of the causative virus human 
herpesvirus-8 (HHV-8) in Southern Africa [22], and typically advanced HIV stage with late presentation to 
care among ART initiators. This is especially true during the relatively early period of ART scale-up 
analyzed, which began in Malawi in 2004. KS burden may therefore still decline as the national ART 
program matures [23] with earlier and more widespread application of ART under ‘treat all’ guidelines 
[24]. 
Reflecting late presentation to care, advanced WHO stage was associated with increased KS incidence, 
although this association was not observed for those presenting to care with stage 4 disease perhaps 
owing to differences in competing risk of death and prevalence of individuals who already had KS at ART 
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initiation. Advanced HIV stage was associated with a 40% increase in KS incidence. Cervical cancer was 
the second most common cancer, and more advanced WHO stage was not associated with increased 
incidence of cervical cancer in our study. These findings might suggest KS burden will be more 
immediately impacted by earlier ART application in SSA than cervical cancer, as also suggested by early 
epidemiologic data from Uganda and Botswana showing modest incidence declines for KS but not 
cervical cancer [25, 26]. 
We also observed a range of NADC even among Malawians with relatively advanced HIV prior to ART 
initiation. While NADC incidence rates were low overall, our findings highlight the heterogeneous cancer 
burden among Malawian ART initiators beyond KS and cervical cancer, as also suggested by other 
regional studies [25-27]. The highest incidence rates observed were for breast, esophageal, other female 
reproductive, eye and conjunctiva, and bladder cancers. Of these, other female reproductive cancers 
and bladder cancer have confirmed etiologic associations with infectious pathogens (human papilloma 
virus and schistosomiasis, respectively), but associations with HIV in SSA are uncertain. For esophageal 
cancer, there is no known infectious etiology [28], although a Zambia case-control study suggested 
possible association with HIV [29]. For breast cancer, large studies from high-income countries have 
repeatedly shown reduced risk among HIV-infected individuals [3]. However, HIV prevalence among 
breast cancer patients in Botswana is substantially higher than the general population [26]. Our work 
and that of others thus highlight the need for larger and more definitive epidemiologic studies to define 
relationships between HIV and cancer which may be unique to SSA, to inform comprehensive, holistic 
cancer screening and prevention programs in regional ART clinics.  
The lower than expected incidence of lymphomas and NADC in our study is likely due to underdiagnosis. 
Geographical differences in screening and diagnostic confirmation  likely contributed to overall 
completeness of cancer ascertainment by the registry, and therefore record linkage performance. This 
observation is similar to the overall context of cancer ascertainment in SSA, for which regional 
limitations have been extensively described [30]. Cancer awareness is often low but improving among 
patients and clinicians in Malawi, and ability to obtain diagnostic tissue from deep visceral sites is more 
challenging than from more accessible sites. In addition, a single pathology center in Blantyre provided 
services to the entire country during the study period, and only approximately one-fifth of all cancer 
cases were thus pathologically confirmed. Lymphomas may be particularly susceptible to misdiagnosis, 
and studies from Uganda and Malawi have shown that lymphomas are commonly clinically 
misdiagnosed as tuberculosis [31, 32]. Our study may also be subject to underreporting of cancer 
incidence during late patient follow-up. Cancer surveillance after 2010 was limited to central hospitals, 
therefore diagnoses occurring during follow-up beyond 2010 may be less completely captured by the 
registry.  
The Malawi HIV-Cancer Match Study used probabilistic record linkage algorithms to ascertain cancer 
outcomes at centers of excellence for HIV care. This is one of the largest epidemiological studies of its 
kind in SSA to provide a comprehensive overview of the cancer burden among individuals receiving ART. 
We used information on active patient follow-up to construct a retrospective cohort of approximately 
29,000 new ART initiators.  Our study leveraged probabilistic methods and extensive clinical review to 
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link data from Malawi’s national cancer registry with existing electronic medical systems supporting ART 
delivery within large HIV clinics. We performed validation of cancer outcomes through extensive clerical 
and clinical review of matched cases.  
Our study has downstream implications for strengthening health systems in Malawi. Registry data 
matches are an important mechanism for providing HIV clinics with NADC and other non-communicable 
disease outcomes. Routine queries of HIV point-of-care clinics and further validation studies may 
improve cancer registration among HIV-infected populations in SSA. While our study used high quality 
data from HIV clinics participating in the International epidemiologic Databases to Evaluate AIDS (IeDEA) 
consortium, improving data quality and completeness of cancer diagnoses outside of HIV centers of 
excellence is a long-term priority. Interdisciplinary collaboration between HIV and cancer systems is of 
continued importance to build efficient and complete public health data resources in low-income 
settings [33]. 
In conclusion, we provide the first comprehensive baseline description of cancer burden against which 
to monitor cancer control efforts for HIV-infected populations in Malawi.  Our findings demonstrate an 
ongoing high burden of KS and cervical cancer in a young, urban patient population, and the importance 
of integrated screening and management of KS and cervical cancer in ART programs. Longer follow-up 
and additional linkages may be needed to monitor these populations as they age into a demographic 
group where NADC are most common. Nearly 2.3 million people with HIV over 50 years are African, 
greater than half the global burden, and demographic shifts are expected to continue under expanded 
ART guidelines for earlier treatment and the growing number of people accessing ART [34]. In high 
income countries, the burden and incidence of KS and NHL declined substantially since the introduction 
of ART [35-37], but the NADC burden has actually increased with growth and aging of HIV-infected 
populations, as well as declines in competing causes of death [36, 38]. Whether cancer trends in high-
income countries will be replicated among HIV populations in Africa remains uncertain. Validation of our 
findings through companion studies in other parts of SSA is needed, as well as longer-term studies to 
monitor potential shifts in cancer distribution under expanded ART guidelines. Continued investment in 
high-quality cancer surveillance will be essential to inform evidence-based national cancer control 
efforts in SSA. Preparing African healthcare systems for the impending challenges of caring for aging HIV 
populations, and forthcoming non-communicable disease burden, is essential [39, 40].  
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Table 1. Characteristics of new ART initiators enrolled at Queen Elizabeth Hospital HIV clinic, Blantyre, 
and Lighthouse Trust HIV Clinic, Lilongwe, Malawi 
Lighthouse Trust (2007-2010) 
Queen Elizabeth Central Hospital 
(2000-2010) 
Total cohort 
Person-years at 
risk  Total cohort 
Person-years at 
risk  
N % N % N % N % 
Total 15920 49981 12656 50834 
Sex 
Male 6713 42.2% 19558 39.1% 5529 43.7% 20591 40.5%
Female 9207 57.8% 30423 60.9% 7127 56.3% 30243 59.5%
Age category (years) 
<16  706 4.6% 2181 4.5% 1730 13.7% 6183 12.2%
16-25 1641 10.7% 4881 10.1% 1203 9.5% 4049 8.0%
26-35 6273 40.8% 19980 41.5% 4628 36.6% 18641 36.7%
36-45 4527 29.5% 14422 30.0% 3283 25.9% 14217 28.0%
46-55 1624 10.6% 5013 10.4% 1321 10.4% 5799 11.4%
56+ 595 3.9% 1652 3.4% 491 3.9% 1945 3.8%
missing 554 - 1851 - - - 
Age at enrollment, 
years, median (IQR) 33.3 (27.9, 39.8) 33.5 (16.7, 40.9) 
WHO stage 
1 or 2 4852 30.5% 17693 35.4% 4181 33.0% 18793 37.0%
3 6499 40.8% 19362 38.7% 6261 49.5% 26123 51.4%
4 2207 13.9% 4855 9.7% 2010 15.9% 5477 10.8%
Not 
applicable/unknown 2362 14.8% 8070 16.1% 204 1.6% 441 0.4% 
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Table 2. Cancer incidence rates by timing of diagnosis after ART initiation 
Men Women 
Incidence 
Rate (95% CI) 
Incidence 
Rate (95% CI) 
All sites, total 765.5 (621.7, 909.3) 643.3 (543.6, 743.0) 
Early incidence 534.7 (417.5, 651.9) 399.1 (324.5, 473.7) 
Late incidence 230.8 (147.5, 314.2) 244.2 (178.0, 310.4) 
Kaposi sarcoma  
Early incidence 525.0 (407.9, 642.1) 371.7 (298.2, 445.2) 
Late incidence  203.4 (126.3, 280.5) 202.8 (140.0, 265.6) 
Cervical cancer 
Early incidence - 13.7 (7.7, 19.7) 
Late incidence  - 22.9 (9.0, 36.8) 
Incidence rates are per 100,000 person-years on ART and are age-adjusted to the 2007 Malawi standard 
population. Cancer sites include invasive cases only. Early incidence is defined as 4 to 24 months after start of ART; 
late incidence is defined as >24 months after start of ART. 
95%CI : 95% Confidence Interval. 
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Table 3. Cancer incidence rates by WHO clinical stage at time of cohort enrollment 
Incidence 
Rate (95% Cl) IRR (95% Cl) 
Kaposi sarcoma 
stage 1 or 2 145.3 (109.0, 181.6) 1. 
stage 3 202.8 (150.3, 255.4) 1.4 (1.1, 1.7) 
stage 4 150.2 (106.5, 193.9) 1.0 (0.8, 1.3) 
Cervical cancer 
stage 1 or 2 12.6 (6.0, 19.1) 1. 
stage 3 21.3 (8.0, 34.7) 1.7 (0.9, 3.2) 
stage 4 1.0 (0.0, 2.4) 0.1 (0.0, 0.3) 
Incidence rates are per 100,000 person-years on ART and are age-adjusted to the 2007 Malawi standard 
population. Cancer sites include invasive cases only. Cases with missing WHO stage at enrollment were excluded 
(Kaposi sarcoma n=229; cervical cancer n=2). 
95%CI : 95% Confidence Interval. IRR: Incidence Rate Ratio. 
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Figure Title:  
Figure 1. Age-adjusted cancer incidence rates among new ART users in Malawi, 2000-2010. 
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